HKSE · 3839.HK
CPBIO Holding Company Limited
HK$7.81+HK$0.19 (+2.43%)
CPBIO Holding Company Limited’s quoted price sits in the upper half of its reported 52-week range, 21.08% below the high.
Loading market information…
OTC · EVFM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Evofem Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Evofem Biosciences, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$914.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Evofem Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $4.84M-6.75% vs estimate |
| Q3 2024 | Nov 14, 2024 | -$0.02+99.73% vs estimate | $5.11M-76.44% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$7.81+HK$0.19 (+2.43%)
CPBIO Holding Company Limited’s quoted price sits in the upper half of its reported 52-week range, 21.08% below the high.
$0.03-$0.00 (0.0%)
Bionoid Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.3% below the high.
$0.14-$0.04 (-22.22%)
International Stem Cell Corporation’s quoted price sits in the lower half of its reported 52-week range, 74.07% below the high.
$0.06$0.00 (0.0%)
Unity Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.19% below the high.
$0.01$0.00 (0.0%)
Biocure Technology Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.71% below the high.
$0.00$0.00 (0.0%)
Certive Solutions Inc.’s quoted price sits in the lower half of its reported 52-week range, 15.79% below the high.
$0.00$0.00 (0.0%)
Marizyme, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.3% below the high.
$0.00$0.00 (0.0%)
Body and Mind Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
